Intellipharmaceutics International Inc. (IPCIF)
Market Cap | 3.84M |
Revenue (ttm) | 904,946 |
Net Income (ttm) | -3.17M |
Shares Out | 38.42M |
EPS (ttm) | -0.10 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 3,000 |
Open | 0.100 |
Previous Close | 0.060 |
Day's Range | 0.100 - 0.100 |
52-Week Range | 0.020 - 0.150 |
Beta | 0.46 |
Analysts | n/a |
Price Target | n/a |
Earnings Date | n/a |
About IPCIF
Intellipharmaceutics International Inc., a pharmaceutical company, researches, develops, and manufactures novel and generic controlled-release and targeted-release oral solid dosage drugs in the United States. It develops various drug delivery systems, product candidates, and a pipeline of products based on its patented Hypermatrix technology in various therapeutic areas, including neurology, cardiovascular, gastrointestinal tract, diabetes, and pain. The company offers Focalin XR, a dexmethylphenidate hydrochloride extended-release capsule for... [Read more]
Financial Performance
In 2022, IPCIF's revenue was $65,728, a change of 0.00% compared to the previous year's $65,728. Losses were -$2.89 million, 0.00% compared to 2021.
Financial StatementsNews
![](https://cdn.snapi.dev/images/v1/v/c/press1-2480610.jpg)
Intellipharmaceutics Announces Downgrade to OTC Expert Market
TORONTO, ON / ACCESSWIRE / June 14, 2024 / Intellipharmaceutics International Inc. (OTCQB:IPCIF) and (TSX:IPCI.H) ("Intellipharmaceutics" or the "Company"), announced today that its common stock, curr...
![](https://cdn.snapi.dev/images/v1/v/3/press5-2323249.jpg)
Intellipharmaceutics International Inc. Announces Transfer of Listing to NEX and New Stock Option Plan
TORONTO, ON / ACCESSWIRE / March 13, 2024 / Intellipharmaceutics International Inc. (OTCQB:IPCIF)(TSX:IPCI) - ("Intellipharmaceutics" or the "Company"), a pharmaceutical company specializing in the re...
![](https://cdn.snapi.dev/images/v1/4/v/press1-2311709.jpg)
Intellipharmaceutics Announces Cease Trade Order
TORONTO, ON / ACCESSWIRE / March 6, 2024 / Intellipharmaceutics International Inc. (OTCQB:IPCIF)(TSX:IPCI) ("Intellipharmaceutics" or the "Company"), a pharmaceutical company specializing in the resea...
![](https://cdn.snapi.dev/images/v1/t/0/press16-2294866.jpg)
Intellipharmaceutics Announces Its Expected Delay in Filing Annual Audited Financial Statements and Annual Information Form
TORONTO, ON / ACCESSWIRE / February 26, 2024 / Intellipharmaceutics International Inc. (OTCQB:IPCIF)(TSX:IPCI) ("Intellipharmaceutics" or the "Company"), a pharmaceutical company specializing in the r...
![](https://cdn.snapi.dev/images/v1/f/u/press1-2268325.jpg)
Intellipharmaceutics International Inc. Announces Stock Option Grant
TORONTO, ON / ACCESSWIRE / February 8, 2024 / Intellipharmaceutics International Inc. (OTCQB:IPCIF)(TSX:IPCI) ("Intellipharmaceutics" or the "Company"), a pharmaceutical company specializing in the re...
![](https://cdn.snapi.dev/images/v1/p/v/press1-2213917.jpg)
Intellipharmaceutics International Inc. Receives Conditional Approval to List on the TSX Venture Exchange
TORONTO, ON / ACCESSWIRE / January 2, 2024 / Intellipharmaceutics International Inc. (OTCQB:IPCIF)(TSX:IPCI) - ("Intellipharmaceutics" or the "Company"), a pharmaceutical company specializing in the r...
![](https://cdn.snapi.dev/images/v1/n/z/press20-2105595.jpg)
Intellipharmaceutics Announces Third Quarter 2023 Results
TORONTO, ON / ACCESSWIRE / October 16, 2023 / Intellipharmaceutics International Inc. (OTCQB:IPCIF)(TSX:IPCI) ("Intellipharmaceutics" or the "Company"), a pharmaceutical company specializing in the re...
![](https://cdn.snapi.dev/images/v1/2/a/press1-2064558.jpg)
Intellipharmaceutics Reports Director Election Results
TORONTO, ON / ACCESSWIRE / September 14, 2023 / Intellipharmaceutics International Inc. (OTCQB:IPCIF)(TSX:IPCI) ("Intellipharmaceutics" or the "Company"), a pharmaceutical company specializing in the ...
![](https://cdn.snapi.dev/images/v1/m/6/press1-1972532.jpg)
Intellipharmaceutics Announces Second Quarter 2023 Results
TORONTO, ON / ACCESSWIRE / July 14, 2023 / Intellipharmaceutics International Inc. (OTCQB:IPCIF and TSX:IPCI) ("Intellipharmaceutics" or the "Company"), a pharmaceutical company specializing in the re...
![](https://cdn.snapi.dev/images/v1/p/r/press6-1583783.jpg)
Intellipharmaceutics Announces Third Quarter 2022 Results
TORONTO, ON / ACCESSWIRE / October 14, 2022 / - Intellipharmaceutics International Inc. (OTCQB:IPCIF)(TSX:IPCI) ("Intellipharmaceutics" or the "Company"), a pharmaceutical company specializing in the ...
![](https://cdn.snapi.dev/images/v1/u/a/press11-1506814.jpg)
Intellipharmaceutics Signs an Exclusive License & Supply Agreement with Taro Pharmaceuticals Inc. for Desvenlafaxine Extended-Release Tablets
TORONTO, ON / ACCESSWIRE / August 16, 2022 / Intellipharmaceutics International Inc. (OTCQB:IPCIF)(TSX:IPCI) ("Intellipharmaceutics" or the "Company"), a pharmaceutical company specializing in the res...
![](https://cdn.snapi.dev/images/v1/p/r/press12-1463266.jpg)
Intellipharmaceutics Announces Second Quarter 2022 Results
TORONTO, ON / ACCESSWIRE / July 21, 2022 / Intellipharmaceutics International Inc. (OTCQB:IPCIF)(TSX:IPCI) ("Intellipharmaceutics" or the "Company"), a pharmaceutical company specializing in the resea...
![](https://cdn.snapi.dev/images/v1/z/o/press7-1453954.jpg)
Intellipharmaceutics Announces Delay in Filing Second Quarter Results Due July 15, 2022, The Financial Statements Will be Filed By July 21, 2022
TORONTO, ON / ACCESSWIRE / July 15, 2022 / Intellipharmaceutics International Inc. (OTCQB:IPCIF) and (TSX:IPCI) ("Intellipharmaceutics" or the "Company"), a pharmaceutical company specializing in the ...
![](https://cdn.snapi.dev/images/v1/p/r/press11-1321704.jpg)
Intellipharmaceutics Announces First Quarter 2022 Results
TORONTO, ON / ACCESSWIRE / April 14, 2022 / Intellipharmaceutics International Inc. (OTCQB:IPCIF) and (TSX:IPCI) ("Intellipharmaceutics" or the "Company"), a pharmaceutical company specializing in the...
![](https://cdn.snapi.dev/images/v1/p/r/press13-1255596.jpg)
Intellipharmaceutics Announces Fiscal Year 2021 Results
TORONTO, ON / ACCESSWIRE / February 28, 2022 / Intellipharmaceutics International Inc. (OTCQB:IPCIF and TSX:IPCI) ("Intellipharmaceutics" or the "Company"), a pharmaceutical company specializing in th...
![](https://cdn.snapi.dev/images/v1/2/1/press6-1185614.jpg)
Intellipharmaceutics Mourns the Death of Valued Board Member Kenneth Eugene Keirstead
TORONTO, ON / ACCESSWIRE / January 13, 2022 / Intellipharmaceutics International Inc. (OTCQB:IPCIF) and (TSX:IPCI) ("Intellipharmaceutics" or the "Company"), a pharmaceutical company specializing in t...
![](https://cdn.snapi.dev/images/v1/s/j/press3-1160884.jpg)
Intellipharmaceutics Comments on Recent Trading Activity
TORONTO, ON / ACCESSWIRE / December 22, 2021 / Intellipharmaceutics International Inc. (OTCQB:IPCIF and TSX:IPCI) ("Intellipharmaceutics" or the "Company"), a pharmaceutical company specializing in th...
![](https://cdn.snapi.dev/images/v1/p/r/press11-1052210.jpg)
Intellipharmaceutics Announces Third Quarter 2021 Results
TORONTO, ON / ACCESSWIRE / October 15, 2021 / Intellipharmaceutics International Inc. (OTCQB:IPCIF) and (TSX:IPCI) ("Intellipharmaceutics" or the "Company"), a pharmaceutical company specializing in t...
![](https://cdn.snapi.dev/images/v1/p/r/press1-913789.jpg)
Kim Spencer McPhee Barristers, P.C. Publishes This Notice of Certification and Notice of Hearing for Settlement Approval of the Intellipharmaceutics International Inc. Securities Class Action
TORONTO--(BUSINESS WIRE)--Kim Spencer McPhee Barristers, P.C. today announces a proposed securities class action settlement regarding Intellipharmaceutics International Inc. (“IPCI”). In 2019, a propo...
![](https://cdn.snapi.dev/images/v1/a/0/press18-779082.jpg)
Intellipharmaceutics Announces Closing of CAD$3.85 Million Non-Brokered Private Placement
TORONTO, ON / ACCESSWIRE / April 22, 2021 / Intellipharmaceutics International Inc. (OTCQB:IPCIF) and (TSX:IPCI) ("Intellipharmaceutics" or the "Company"), a pharmaceutical company specializing in the...
![](https://cdn.snapi.dev/images/v1/p/r/press4-765436.jpg)
Intellipharmaceutics Announces First Quarter 2021 Results
TORONTO, ON / ACCESSWIRE / April 14, 2021 / Intellipharmaceutics International Inc. (OTCQB:IPCIF)(TSX:IPCI) ("Intellipharmaceutics" or the "Company"), a pharmaceutical company specializing in the rese...
![](https://cdn.snapi.dev/images/v1/g/s/press19-701825.jpg)
Intellipharmaceutics Announces Fiscal Year 2020 Results
TORONTO, ON / ACCESSWIRE / March 1, 2021 / Intellipharmaceutics International Inc. (OTCQB:IPCIF) and (TSX:IPCI) ("Intellipharmaceutics" or the "Company"), a pharmaceutical company specializing in the ...